Latest News-DAEWOONG PHARMACEUTICAL Mediaroom_Page

Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial

- Evaluation of Bersiporocin's safety and efficacy against a total of 102 patients over 24 weeks -...

2023-02-06 13:00 2149

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

* Daewoong Pharmaceutical to receive up to $76M upfront and development milestone payment plus a...

2023-01-31 14:43 4938

Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea

"Expected to change GERD drug market landscape" * Application for product approval of Fexuclue, ...

2023-01-26 09:14 3281

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

* Delivers new drug for two consecutive years by obtaining product license on "Envlo", Korea's 36...

2022-12-06 20:00 1998

Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40...

2022-11-15 20:00 1939

Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030

* Highly anticipated to be an effective therapeutic for its excellent efficacies in reducing bloo...

2022-11-02 09:00 2486

CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA

* Embarking on a successful journey of exporting its home-grown product technology toNorth Americ...

2022-08-04 21:00 2852

CGBio Signing a North America Out-license Contract on

Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever

- Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in op...

2022-07-28 21:00 2970

Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

* US Food and Drug Administration (FDA) fast-tracks idiopathic pulmonary fibrosis treatment DWN1...

2022-07-20 21:00 1842

Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug

Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis

- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patie...

2022-06-24 21:00 3927

Daewoong Pharmaceutical announced first-quarter 2022 results

- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high...

2022-05-05 21:00 2295

HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative

* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnolog...

2022-04-13 08:00 1929

/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/

We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers s...

2022-04-12 15:34 2280

Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines

- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong ...

2022-03-29 09:00 2936

Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy

SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the ...

2022-02-25 22:00 3605

Latest News